Skip to main content
SpringerLink
Log in

Vedolizumab not associated with increase in malignancies

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Card T, et al. Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data. Alimentary Pharmacology and Therapeutics : 20 Nov 2019. Available from: URL: http://doi.org/10.1111/apt.15538

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vedolizumab not associated with increase in malignancies. Reactions Weekly 1781, 12 (2019). https://doi.org/10.1007/s40278-019-71835-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-71835-3

Search

Navigation